Vectura Group plc today announces its preliminary results for the year ended 31 December 2018. For full details, please click here.
Commenting on the preliminary results, James Ward-Lilley, Chief Executive Officer of Vectura, said:
“Focused execution of the Group’s strategy resulted in strong financial and operational performance in 2018. Our generic portfolio is progressing well with the VR315 repeat clinical trial on track to enable Hikma resubmission in 2019, and the signing of the global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio being a major catalyst for future value. Despite the disappointment of the VR475 Phase III study, we continue to make good progress with our nebulised programmes, including development of three new specialist opportunities. We look forward to sustaining our operational performance and providing an update on a number of important catalysts in 2019 including VR315 resubmission, partnering of VR647, further progress on our new nebulised assets and Phase III study completion for QVM149, our ICS/LAMA/LABA therapy for asthma, partnered with Novartis.”
James Ward-Lilley, Chief Executive Officer, and Paul Fry, Chief Financial Officer, presented the Preliminary Results for analysts earlier today, 26 March 2019. You can access the presentation slides and a link to a webcast here.